Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03245736|
Recruitment Status : Completed
First Posted : August 10, 2017
Last Update Posted : January 18, 2020
|Condition or disease||Intervention/treatment||Phase|
|Ovary Cancer Cervix Cancer Endometrium Cancer Bladder Cancer Prostate Cancer Esophagus Cancer Lung Cancer, Nonsmall Cell Squamous Cell Carcinoma of the Head and Neck||Drug: Tisotumab Vedotin||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||5 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multi-center, Open-label Trial Investigating the Efficacy and Safety of Continued Treatment With Tisotumab Vedotin in Patients With Solid Tumors Known to Express Tissue Factor.|
|Actual Study Start Date :||August 23, 2017|
|Actual Primary Completion Date :||January 10, 2019|
|Actual Study Completion Date :||January 10, 2019|
Experimental: Tisotumab Vedotin
All patients will be administered tisotumab vedotin (HuMax-TF-ADC) in 21 day treatment cycles.
Drug: Tisotumab Vedotin
All patients in the trial will be administered tisotumab vedotin (HuMax-TF-ADC).
- Adverse events [ Time Frame: An expected average of 6 months ]Adverse events measured throughout the study from first treatment until end of trial
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03245736
|United States, Florida|
|Miami, Florida, United States, 33136|
|Johann de Bono|
|Chelsea, United Kingdom, SM2 5PT|
|Beatson Cancer Centre|
|Glasgow, United Kingdom|
|Manchester, United Kingdom, M20 4BX|
|Study Director:||Reshma Rangwala, Dr||Genmab|